STERIS plc $STE Shares Purchased by Congress Asset Management Co.

Posted by Brian Himes on Oct 6th, 2026

Congress Asset Management Co. grew its position in STERIS plc (NYSE:STE – Free Report) by 2.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 174,713 shares of the medical equipment provider’s stock after acquiring an additional 3,746 shares during the quarter. Congress Asset Management Co.’s holdings in STERIS were worth $36,691,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP increased its position in shares of STERIS by 21.9% during the second quarter. Wellington Management Group LLP now owns 3,502,897 shares of the medical equipment provider’s stock valued at $737,605,000 after purchasing an additional 629,532 shares during the period. Janus Henderson Group PLC lifted its position in STERIS by 25.7% in the first quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock worth $411,995,000 after purchasing an additional 380,504 shares during the period. Franklin Resources Inc. lifted its position in STERIS by 0.6% in the fourth quarter. Franklin Resources Inc. now owns 1,252,844 shares of the medical equipment provider’s stock worth $317,621,000 after purchasing an additional 7,840 shares during the period. Dimensional Fund Advisors LP lifted its position in STERIS by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,113,845 shares of the medical equipment provider’s stock worth $246,295,000 after purchasing an additional 46,391 shares during the period. Finally, Bessemer Group Inc. boosted its stake in STERIS by 8.8% during the first quarter. Bessemer Group Inc. now owns 1,048,636 shares of the medical equipment provider’s stock worth $231,883,000 after buying an additional 85,188 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Price Performance

STE stock traded down $2.51 during trading on Tuesday, hitting $208.56. The company had a trading volume of 909,383 shares, compared to its average volume of 769,534. The company has a fifty day moving average price of $224.07 and a two-hundred day moving average price of $218.18. The company has a current ratio of 1.91, a quick ratio of 1.35 and a debt-to-equity ratio of 0.23. The company has a market cap of $20.33 billion, a P/E ratio of 25.50 and a beta of 0.92. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44.

STERIS (NYSE:STE – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.49 by $0.10. STERIS had a return on equity of 14.34% and a net margin of 13.34%.The firm had revenue of $1.49 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the business posted $2.34 earnings per share. The business’s revenue was up 7.3% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Equities research analysts expect that STERIS plc will post 11.12 earnings per share for the current fiscal year.

STERIS Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 25th. Stockholders of record on Friday, September 4th were issued a $0.69 dividend. This represents a $2.76 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend was Friday, September 4th. This is a positive change from STERIS’s previous quarterly dividend of $0.63. STERIS’s payout ratio is currently 33.74%.

Analysts Set New Price Targets

STE has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Piper Sandler reiterated an “overweight” rating and set a $275.00 target price (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. UBS Group lowered their target price on shares of STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of STERIS in a research report on Monday, August 24th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus target price of $271.33.

Read Our Latest Stock Report on STERIS

Insider Buying and Selling at STERIS

In related news, Director Mohsen Sohi sold 4,058 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total transaction of $956,795.24. Following the completion of the sale, the director owned 24,305 shares in the company, valued at $5,730,632.90. This trade represents a 14.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.12% of the company’s stock.

About STERIS

(Free Report)

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, surgical procedures, and the manufacture of healthcare and pharmaceutical products. The company serves healthcare providers, pharmaceutical and biotechnology manufacturers, and other organizations that require controlled, sterile environments.

Its Healthcare segment offers sterilization and decontamination equipment, operating-room products, surgical instruments, endoscopy products, consumables, and related maintenance and procedural services.